Torrent Pharmaceuticals
Torrent Pharma delivered a strong Q3 FY26 with 18% revenue growth to ₹3,333 crore and 19% EBITDA growth to ₹1,088 crore, driven by double-digit expansion in India (+14%) and Brazil (+27% reported, +10% constant curren...
Torrent Pharmaceuticals vs Akums Drugs & Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Akums Drugs &
Akums delivered a strong Q3 FY26 with operating revenue of ₹1,160 crore (+14.8% YoY) and EBITDA of ₹147 crore (+21% YoY), driven by 16% volume growth in CDMO and recovery in international branded formulations.
Result Snapshot
Revenue₹3,333 Cr₹1,160 Cr
PAT₹635 Cr₹68 Cr
EBITDA Margin32.9%12.7%
Sentimentbullishbullish
Key Quotes
Our two largest branded markets, India and Brazil, each continue to deliver healthy double-digit growth. India business grew at 14% and Brazil grew at 27%.
Our healthy operating performance was characterized by strong execution across multiple key segments. CDMO registered a healthy topline growth of more than 16% driven by strong volumes.